Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2011

View Archived Issues

Novel phosphodiesterase 10A inhibitors synthesized

Lotus Tissue Repair raises funds to advance treatment for dystrophic epidermolysis bullosa

Johns Hopkins University and Innogene Kalbiotech begin trial for lung cancer vaccine

ISC-4 exhibits safety and antitumor activity in murine model of human colon cancer

Preclinical study supports further evaluation of dovitinib in Waldenstrom's macroglobulinemia

Leukothera shows synergistic activity with chemotherapeutic agents in leukemia cell lines

New lysophospholipid S1P1 receptor agonists presented by Almirall

Roche discloses new glycogen synthase activators

Bristol-Myers Squibb and Innate Pharma enter global agreement for IPH-2102

INV-144 enters phase IIa trial to slow kidney disease in patients with hypertension and diabetes

Novel nuclear receptor related 1 receptor ligands patented by Sanofi

Novel PI3K inhibitors prepared

Dainippon Sumitomo and AstraZeneca claim new Toll-like receptor modulators

Vantia Therapeutics raises funds to develop VA-106483 and VA-111913

Roche discloses novel series of monoamine reuptake inhibitors

Dual mTORC1/mTORC2 inhibition may enhance treatment of acute myeloid leukemia

Metabolic Solutions receives funds from the Alzheimer's Drug Discovery Foundation

Zafgen secures financing for phase II trial in obesity

INNO-206 shows safety in ongoing phase Ib trial in soft tissue sarcoma

IDMC recommmends continuation of phase III VENICE trial of Zaltrap in advanced prostate cancer

Merck KGaA to discontinue development of Toll-like receptor 9 agonist IMO-2055

Amylin Pharmaceuticals, Lilly and Alkermes report on tQT study of Bydureon

Phase III EXIST-1 trial of Afinitor in tuberous sclerosis meets primary endpoint

TMC-435 receives FDA fast track status in chronic hepatitis C genotype 1

Amsterdam Molecular Therapeutics requests reexamination of MAA for gene therapy Glybera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...